Home›Trial›NCT06449209
🔬NCT06449209Phase 2ACTIVE NOT RECRUITING

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Study Summary

This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.

Conditions
Extensive-stage Small-cell Lung CancerSmall-cell Lung Cancer
Interventions / Drugs
BNT327 Dose Level 1 (DL1)BNT327 Dose Level 2 (DL2)EtoposideCarboplatinPaclitaxelTopotecan
View on ClinicalTrials.gov ↗
Sponsor
BNTX
BioNTech SE
mRNA Therapeutics
F20/100
Study Details
Enrollment110 participants
Primary Completion—
Lead SponsorBioNTech SE
Data Retrieved2026-04-11 02:55:25.057706+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.